PT  - JOURNAL ARTICLE
AU  - Olivier Martinez
AU  - Jane Sosabowski
AU  - John Maher
AU  - Sophie Papa
TI  - New Developments in Imaging Cell-Based Therapy
AID  - 10.2967/jnumed.118.213348
DP  - 2019 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 730--735
VI  - 60
IP  - 6
4099  - http://jnm.snmjournals.org/content/60/6/730.short
4100  - http://jnm.snmjournals.org/content/60/6/730.full
SO  - J Nucl Med2019 Jun 01; 60
AB  - Cancer immunotherapy is now established as a central therapeutic pillar in hematologic oncology. Cell-based therapies, with or without genetic modification ex vivo, have reached the clinic as the standard of care in limited indications and remain the subject of intense preclinical and translational development. Expanding on this, related therapeutic approaches are in development for solid-tumor and nonmalignant indications, broadening the scope of this technology. It has long been recognized that in vivo tracking of infused cellular therapies would provide unique opportunities to optimize their efficacy and aid in the assessment and management of toxicity. Recently, we have witnessed the introduction of novel tracers for passive labeling of cell products and advances in the introduction and use of reporter genes to enable longitudinal imaging. This review highlights the key developments over the last 5 y.